Alaunos Therapeutics (TCRT) director receives 5,622 shares

Rhea-AI Filing Summary

Alaunos Therapeutics director Robert W. Postma received 5,622 shares of common stock on January 12, 2026, as compensation in lieu of board fees at a price of $2.89 per share. Following this grant, he directly holds 43,872 Alaunos shares. He also reports indirect beneficial ownership of 24 shares through his spouse's IRA and 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Postma Robert W

(Last) (First) (Middle)

C/O ALAUNOS THERAPEUTICS, INC.

501 E. LAS OLAS BLVD. SUITE 300

(Street)

FORT LAUDERDALE FL 33301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		A		5,622(1)	A	$2.89	43,872	D
Common Stock								24	I	By spouse's IRA
Common Stock								62,416(2)	I	By WaterMill Asset Management Corp.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock issued in lieu of board fees.

2. The shares are directly held by WaterMill Asset Management Corp. ("WaterMill"). The Reporting Person serves as the principal of WaterMill.

	/s/ Postma, Robert W	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Alaunos Therapeutics (TCRT) report in this Form 4?

The filing reports that director Robert W. Postma acquired 5,622 shares of Alaunos Therapeutics common stock on January 12, 2026, as indicated by transaction code "A" for an acquisition.

What was the price and nature of the Alaunos Therapeutics (TCRT) shares acquired?

The 5,622 common shares were issued at a price of $2.89 per share and are described as shares of common stock issued in lieu of board fees, meaning they were received as director compensation rather than bought in the open market.

How many Alaunos Therapeutics (TCRT) shares does Robert W. Postma now own directly?

After the reported transaction, Robert W. Postma beneficially owns 43,872 shares of Alaunos Therapeutics common stock in direct ownership.

What indirect holdings of Alaunos Therapeutics (TCRT) stock are reported for Robert W. Postma?

The filing shows indirect beneficial ownership of 24 shares held by his spouse's IRA and 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal.

Does this Form 4 involve any derivative securities for Alaunos Therapeutics (TCRT)?

No derivative securities are listed in Table II. The reported holdings all relate to common stock, with no options, warrants, or other derivatives shown.

What is the relationship of the reporting person to Alaunos Therapeutics (TCRT)?

Robert W. Postma is identified in the filing as a director of Alaunos Therapeutics, Inc., and the Form 4 is filed by one reporting person.